Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Article . 2025
License: CC BY
Data sources: ZENODO
International Journal of Medical Science and Clinical Research Studies
Article . 2025 . Peer-reviewed
Data sources: Crossref
ZENODO
Article . 2025
License: CC BY
Data sources: Datacite
ZENODO
Article . 2025
License: CC BY
Data sources: Datacite
 View all 3 versions
Claim

Successful Use of Dupilumab in Bullous Pemphigoid: A Series of 3 Cases in Mexico

descriptionPublicationkeyboard_double_arrow_right Article 10 Mar 2025Publisher:Everant JournalsJournal:International Journal of Medical Science and Clinical Research Studies, volume 5 (issn: 2767-8326, Copyright policy )
Authors: Pablo Belmont Nava; Carol Estefania Márquez-Maldonado; Lucia Achell Nava; Guadalupe Maldonado Colin; Dolores Maribel Arellano Vivero;

doi: 10.47191/ijmscrs/v5-i03-01 , 10.5281/zenodo.14958235 , 10.5281/zenodo.14958236

Successful Use of Dupilumab in Bullous Pemphigoid: A Series of 3 Cases in Mexico

Abstract

This review explores three recent case reports detailing the successful treatment of bullous pemphigoid (BP) with Dupilumab, a monoclonal antibody targeting interleukin-4 receptor alpha subunit (IL-4Rα). Each case highlights unique clinical presentations, treatment approaches, and outcomes, underscoring Dupilumab's potential as a therapeutic option in BP management.

Related Organizations
Keywords

Bullous pemphigoid, Dupilumab, Autoimmune blistering disease, IL-4 receptor alpha antagonist, Case series, Dermatology, Refractory bullous pemphigoid, Targeted therapy.

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    		 Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    		 Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
Green